60 Degrees Pharmaceuticals (SXTP) Current Leases (2022 - 2023)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Current Leases of $13650.0 for Q4 2023, up 5.0% year-over-year from $13000.0 in Q4 2022, and down 49.07% quarter-over-quarter from $26800.0 in Q3 2023.
60 Degrees Pharmaceuticals (SXTP) Current Leases (2022 - 2023) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Current Leases for 2 consecutive years, with $13650.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Current Leases rose 5.0% year-over-year to $13650.0; the TTM figure through Dec 2023 stood at $13650.0 (up 5.0% YoY), while the FY2023 annual figure was $13650.0, up 5.0% from the prior year.
- Current Leases retreated to $13650.0 in Q4 2023 per SXTP's latest filing, from $26800.0 in the prior quarter.
- Across five years, Current Leases topped out at $39470.0 in Q2 2023 and bottomed at $13000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.05 Mn | 2.03 Mn | 56,798.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13,650.00 |
| Sep 30, 2023 | 26,800.00 |
| Jun 30, 2023 | 39,470.00 |
| Dec 31, 2022 | 13,000.00 |